Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
创建时间：
1900-01-01
